Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
暂无分享,去创建一个
Sakae Tanaka | H. Genant | D. M. van der Heijde | T. Yoneda | H. Yamanaka | Yoshiya Tanaka | T. Takeuchi | S. Soen | N. Okubo | T. Nitta